Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 2, 2026, 1:25 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 1,017 matching trials from the live ClinicalTrials.gov search.
Conditions
Sepsis
Interventions
High Fiber, Low Fiber
Dietary Supplement
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
New York, New York
Conditions
Airway Control, Anesthesia, Intubation, Complication
Interventions
Ketamine, Etomidate
Drug
Lead sponsor
Hennepin Healthcare Research Institute
Other
Eligibility
18 Years and older
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Mycoses, Fungemia, Central Nervous System Fungal Infections, Lung Diseases, Fungal
Interventions
Anidulafungin, Fluconazole
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
6
States / cities
Los Angeles, California • Miami, Florida • Ann Arbor, Michigan + 3 more
Conditions
Systemic Infection
Interventions
Observational Study
Other
Lead sponsor
BioFire Diagnostics, LLC
Industry
Eligibility
Up to 17 Years
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
3
States / cities
Los Angeles, California • Atlanta, Georgia • Kansas City, Missouri
Conditions
Sepsis, Septic Shock, Severe Sepsis
Interventions
Severe Sepsis Prediction, Severe Sepsis Detection
Other
Lead sponsor
Dascena
Industry
Eligibility
18 Years and older
Enrollment
2,296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Huntington, West Virginia
Active, not recruiting Not applicable Interventional

Dialysis Catheter Caps Case Feasibility Study

NCT06905080
Conditions
Sterile Catheter, Catheter-related Bloodstream Infections, Dialysis Catheter, Dialysis
Interventions
Catheter Caps Case (C3)
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Jacksonville, Florida
Completed Phase 4 Interventional Results available

Prophylactic Antimicrobial Catheter Lock

NCT00571259
Conditions
Bacteremia
Interventions
Heparin 1000U/mL, 4% Sodium Citrate with Gentamicin 320 mcg/mL
Drug
Lead sponsor
Satellite Healthcare
Other
Eligibility
Not listed
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
Mountain View, California
Conditions
T-cell Lymphoma, NK-Cell Lymphoma, T-cell Prolymphocytic Leukemia, T-cell Large Granular Lymphocytic Leukemia, Chronic Lymphoproliferative Disorder of NK Cells, Aggressive NK-cell Leukemia, Systemic Epstein-Barr Virus Positive T-Cell Lymphoproliferative Disease of Childhood (Disorder), Systemic Epstein Barr Virus Positive T-Cell Lymphoproliferative Disease of Childhood, Chronic Active EBV Infection of T-and NK-Cell Type, Systemic Form, Hydroa Vacciniforme-Like Lymphoproliferative Disorder, Adult T-cell Leukemia/Lymphoma, Extranodal NK/T-cell Lymphoma, Nasal Type, Enteropathy-associated T-cell Lymphoma, Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma, Intestinal T-Cell Lymphoma, Not Otherwise Specified, Indolent T-Cell Lymphoproliferative Disorder of the Gastrointestinal Tract, Hepatosplenic T-cell Lymphoma, Subcutaneous Panniculitis-Like T-Cell Lymphoma, Mycosis Fungoides, Sezary Syndrome, Primary Cutaneous Anaplastic Large Cell Lymphoma, Primary Cutaneous T-cell Lymphoma, Primary Cutaneous CD8-Positive Aggressive Epidermotropic T-Cell Lymphoma, Primary Cutaneous Acral CD8-Positive T-Cell Lymphoma, Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T-cell Lymphoma, Follicular T-Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype, Anaplastic Large Cell Lymphoma, ALK-Positive, Anaplastic Large Cell Lymphoma, ALK-negative, Breast Implant-Associated Anaplastic Large Cell Lymphoma
Interventions
Optional Blood Sample and Nail Sample
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
26
States / cities
Duarte, California • San Diego, California • San Francisco, California + 20 more
Conditions
Gastroesophageal Reflux, Presumed Sepsis, Patent Ductus Arteriosus, Chronic Lung Disease, Neurodevelopmental Impairment
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
Up to 5 Days
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Cancer
Interventions
Fentanyl sublingual spray, Placebo
Drug
Lead sponsor
INSYS Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Chandler, Arizona
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous/Nonmalignant Condition, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
cilengitide
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2001
U.S. locations
1
States / cities
Indianapolis, Indiana
Conditions
Bladder Cancer, Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Lung Cancer, Lymphoma, Prostate Cancer, Testicular Germ Cell Tumor, Tobacco Use Disorder, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
nicotine, Usual Care
Drug · Behavioral
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
19 Years to 120 Years
Enrollment
434 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1990
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Substance Use Disorders, Infection, Soft Tissue, Bacteremia, Osteomyelitis Acute, Septic Arthritis
Interventions
Oritavancin
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 88 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder, Metastatic Cancer, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous Condition, Secondary Myelofibrosis, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
Pemetrexed
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 120 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Sepsis
Interventions
Vital Signs at 2 Hours, Confusion Assessment method for the ICU (CAM-ICU)
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 110 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
New York, New York
Conditions
Septic Shock
Interventions
Plasma, Balanced crystalloids
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Houston, Texas
Conditions
Central Line-associated Bloodstream Infection (CLABSI)
Interventions
Not listed
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
New York, New York
Conditions
Sepsis, Acute Respiratory Distress Syndrome (ARDS)
Interventions
Artifical Intelligence-Generated Treatment Recommendations
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
355 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Completed Not applicable Interventional Accepts healthy volunteers Results available

Enteral Glutamine in Reducing Bloodstream Infections in Short Bowel Syndrome Infants

NCT01576003
Conditions
Bloodstream Infections, Short Bowel Syndrome, Development, Nutrition, Biological Markers
Interventions
Glutamine, L-alanine
Drug · Dietary Supplement
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
6 Weeks to 12 Months
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
2
States / cities
Ann Arbor, Michigan • Cincinnati, Ohio
Conditions
Sepsis, Septicemia, Respiratory Failure, Hemodynamic Instability, COVID-19, Cardiac Arrest, Clinical Deterioration
Interventions
eCARTv5 clinical deterioration monitoring, Standard of care control
Device · Other
Lead sponsor
AgileMD, Inc.
Industry
Eligibility
18 Years and older
Enrollment
30,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
3
States / cities
New Haven, Connecticut • Clearwater, Florida • Madison, Wisconsin
Conditions
Immune and Microbial Reconstitution, Systemic Viral Infection, Acute-graft-versus-host Disease, Chronic Graft-versus-host-disease, Recurrent Malignancy, Cytokine Release Syndrome, Allogenic Related Donors, Cell Therapy/Immunotherapy Patients
Interventions
Blood Sample, Stool Sample, Urine Sample, Bronchoalveolar Lavage (BAL) fluid, Gastrointestinal biopsy x 2-4, Skin biopsy, Skin, mouth, and/or ocular swab, Apheresis Product, Final cellular product
Diagnostic Test
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Not listed
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Sepsis, SIRS
Interventions
Nanomix eLab® System molecular diagnostic test (non-interventional)
Other
Lead sponsor
Nanomix
Industry
Eligibility
18 Years and older
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
San Francisco, California
Completed Phase 1 Interventional Accepts healthy volunteers

Impact of Dopamine Infusion on Insulin Secretion in Healthy Subjects

NCT02053935
Conditions
Hyperglycemia, Sepsis
Interventions
Dopamine
Drug
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years to 35 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
The Bronx, New York
Conditions
Gram-Negative Bacterial Infections
Interventions
Cefiderocol, Standard of Care
Drug
Lead sponsor
Shionogi
Industry
Eligibility
Up to 3 Months
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
2
States / cities
Little Rock, Arkansas • Durham, North Carolina